Eucalyptus Health ended its run as an independent company with its acquisition by Hims & Hers. The final valuation stands at $1.1B (post-money). Its shares no longer trade independently.
2 valuations. The latest, $1.1B post-money, was set by the Acquisition by Hims & Hers in Feb 2026.
Founders FundEucalyptus Health runs a group of telehealth brands out of Sydney, treating patients through video consultations, e-prescriptions and delivered medication. Tim Doyle, Charlie Gearside, Benny Kleist and Alexey Mitko founded the company in 2019, starting with Pilot for men's health before adding Juniper for weight management, Software for dermatology and Kin for reproductive health.
Juniper pairs GLP-1 drugs such as Ozempic, Mounjaro and Wegovy with coaching and has supported 200,000 Australian women, while Kin has provided contraceptive pill delivery to more than 50,000 subscribers. Hims & Hers Health agreed to acquire Eucalyptus for up to $1.15 billion in a deal that closed in June 2026.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Eucalyptus Health.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Eucalyptus Health availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Eucalyptus Health included.
No. Eucalyptus Health was acquired by Hims & Hers; its shares do not trade independently.
The last valuation is $1.1B (post-money, Feb 2026).
Lead investors for each round are in the funding timeline.
The closest digital health / telehealth peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
